Consensus guidelines for the diagnosis and management of pyridoxine-dependent epilepsy due to α-aminoadipic semialdehyde dehydrogenase deficiency


1Section of Clinical Genetics and Metabolism, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado
2Department of Pediatrics Emma Children’s Hospital, Amsterdam University Medical Centre, Amsterdam, The Netherlands
3Division of Metabolic Disorders, CHOC Children’s Hospital, Orange, California
4Birmingham Women’s and Children’s NHS Foundation Trust, Birmingham, UK
5Department of Human Genetics, Centre Hospitalier Universitaire Sart-Tilman, Liège, Belgium
6Department of Pediatrics and Neonatology, Máxima Medical Center, Veldhoven, The Netherlands
7Division of Medical Genetics, Department of Specialized Medicine, Montreal Children’s Hospital, McGill University Health Centre, Quéc, Canada
8Genetics and Genomic Medicine, UCL Great Ormond Street Institute of Child Health, London, UK
9Clinic for Paediatric Kidney, Liver, and Metabolic Diseases, Hannover Medical School, Hannover, Germany
10VKS: Dutch Patient Organization for Metabolic Diseases, Zwolle, The Netherlands
11Division of Child Neurology and Inherited Metabolic Disorders, 4th Department of Pediatrics, Aristotle University of Thessaloniki, General Hospital Papageorgiou, Thessaloniki, Greece
12Reference Center for Inborn Errors of Metabolism, Pediatric Unit, University Hospital of Nancy, Nancy, France
13INSERM UMR S 1256, Nutrition, Genetics, and Environmental Risk Exposure (NGERE), Faculty of Medicine of Nancy, University of Lorraine, Nancy, France
14Department of Metabolic Paediatrics, Great Ormond Street Hospital, London, UK
15Division of Pediatric Neurology, Departments of Neurology and Pediatrics, University of Washington, Seattle, Washington
16Department of Pediatrics, Duke University, Durham, North Carolina
17Department of Pediatrics, University of Tripoli, Tripoli, Libya
18National Management of Newborn Screening and Advanced Laboratory Diagnostics in Inborn Errors of Metabolism, Department of Children and Adolescent Medicine, Oslo University Hospital, Oslo, Norway
19Department of Metabolic Medicine, The Royal Children’s Hospital, Melbourne, Victoria, Australia
20Department of Children and Adolescent Medicine, Oslo University Hospital, Oslo, Norway

Received: 14 August 2020 Revised: 21 October 2020 Accepted: 13 November 2020
DOI: 10.1002/jimd.12332
Abstract
Pyridoxine-dependent epilepsy (PDE-ALDH7A1) is an autosomal recessive condition due to a deficiency of α-aminoadipic semialdehyde dehydrogenase, which is a key enzyme in lysine oxidation. PDE-ALDH7A1 is a developmental and epileptic encephalopathy that was historically and empirically treated with pharmacologic doses of pyridoxine. Despite adequate seizure control, most patients with PDE-ALDH7A1 were reported to have developmental delay and intellectual disability. To improve outcome, a lysine-restricted diet and competitive inhibition of lysine transport through the use of pharmacologic doses of arginine have been recommended as an adjunct therapy. These lysine-reduction therapies have resulted in improved biochemical parameters and cognitive development in many but not all patients. The goal of these consensus guidelines is to re-evaluate and update the two previously published recommendations for diagnosis, treatment, and follow-up of patients with PDE-ALDH7A1. Members of the International PDE Consortium initiated evidence and consensus-based process to review previous recommendations, new research findings, and relevant clinical aspects of PDE-ALDH7A1. The guideline development group included pediatric neurologists, biochemical geneticists, clinical geneticists, laboratory scientists, and metabolic dieticians representing 29 institutions from 16 countries. Consensus guidelines for the diagnosis and management of patients with PDE-ALDH7A1 are provided.

KEYWORDS
ALDH7A1, alpha aminoadipic semialdehyde, consensus guidelines, pyridoxine-dependent epilepsy, pyridoxine-responsive seizures

1 | INTRODUCTION
Pyridoxine-dependent epilepsy (PDE, OMIM 266100) is a developmental and epileptic encephalopathy historically defined by clinical or electroencephalogram (EEG) response to pyridoxine. Pharmacologic dose of pyridoxine remains central to the treatment of seizures, although some patients may require additional antiseizure medications for optimal seizure control. However, not all patients respond immediately to a trial of pyridoxine.
Furthermore, patients may present with concomitant findings such as hypoglycemia and lactic acidosis, and other affected patients may present with seizures after the neonatal period. These atypical presentations may further confound and delay the diagnosis, as such patients may not be considered for a therapeutic trial of pyridoxine early in the course of the disease.

The term PDE was initially used to describe the clinical symptoms of neonatal epilepsy in combination with clinical response to pyridoxine. The clinical description itself has been referred to by numerous terms including pyridoxine dependency, pyridoxine-dependent epilepsy and pyridoxine-responsive seizure disorders. While pyridoxine responsiveness reflects the interruption or prevention of seizures when on pyridoxine, a dependency is defined by the recurrence of seizures following withdrawal. Although pyridoxine withdrawal is not common due to the availability of biochemical and genetic testing. The clinical phenotype of pyridoxine dependent or responsive seizures can be caused by many genetic disorders with unique disease mechanisms and treatment implications. This guideline is focused on PDE due to deficiency of α-aminoadipic semialdehyde (α-AASA) dehydrogenase (E.C. 1.2.1.3), which results in accumulation of multiple metabolites including α-AASA, Δ¹-piperideine-6-carboxylate (Δ¹-P6C), and pipecolic acid.

![Figure 1](image.jpg)

**Figure 1** Lysine metabolism and pyridoxine-dependent epilepsy. Pyridoxine-dependent epilepsy is caused by the deficiency of α-aminoadipic semialdehyde (α-AASA) dehydrogenase, which results in the accumulation of multiple metabolites including α-AASA, Δ¹-piperideine-6-carboxylate (Δ¹-P6C), and pipecolic acid.
lysine-restricted diet (substrate reduction therapy) and pharmacologic doses of pyridoxine. The addition of a lysine-restricted diet resulted in decreased accumulation of piperolic acid, α-AASA, and Δ¹-P6C as well as noting improvement in both age-appropriate skills and seizure management.²⁶ Subsequently, several observational studies have reported improved clinical outcomes following adjunct treatment with a lysine-restricted diet,²⁷ pharmacologic doses of arginine, which acts as a competitive inhibitor of lysine transport,²⁸-³⁰ and a combination of pyridoxine, a lysine-restricted diet, and arginine referred to as triple therapy.²⁸,³⁰-³⁴ To standardize the nomenclature in this manuscript, we refer to these additional dietary treatment strategies as lysine reduction therapies.

The initial set of recommendations for diagnosis, treatment and follow up of PDE-ALDH7A1 was published in 2011.²⁵ Treatment recommendations were updated in 2014 to include the use of a lysine-restricted diet.³⁵ Over the last 6 years, several observational studies have reported improved clinical outcomes following treatment with various lysine-reduction therapies. The members of the PDE Consortium reviewed the current state and new developments and elected to revise the recommendations due to the increased number of treatment modalities and observational data focused on improved clinical outcomes. This article summarizes the consensus guidelines for the diagnosis and management of PDE due to the deficiency of α-AASA dehydrogenase.

2 | METHODS

2.1 | Guideline development

Guidelines for PDE-ALDH7A1 were developed by members of the Pyridoxine-Dependent Epilepsy Consortium (www.pdeonline.org), which was established in 2010 to facilitate international collaboration between clinicians and scientists with expertise in PDE-ALDH7A1. The guideline development group consisted of pediatricians specialized in inborn errors of metabolism, adult and pediatric neurologists, biochemical geneticists, clinical geneticists, laboratory scientists, metabolic dieticians, and patient advocates. The guideline development group included representation from 29 institutions across Africa, Asia, Australia, Europe, North America, and South America. The guideline committee members (CRC, LAT, CDMvK) selected a list of topics and transformed them into statements based on previous guidelines, available literature, and expertise of the committee. Two surveys based on these statements were distributed to members of the PDE Consortium. An in-person meeting was moderated on September 2nd, 2019 at the Amsterdam University Medical Centers in Amsterdam, the Netherlands, in conjunction with the fifth international PDE workshop. Communication occurred through e-mails and conference calls throughout the development of the guidelines.

2.2 | Competing interests

All members of the guideline development group were required to report potential conflicts of interest. Most group members (84%) reported no conflict of interest relating to this guideline. Two committee members (5.3%) reported serving on scientific advisory boards, receiving honoraria from pharmaceutical companies, and receiving research support for studies unrelated to PDE-ALDH7A1. Two committee members (5.3%) reported a patent pending for a diagnostic method for PDE-ALDH7A1 that was not discussed in this guideline. Two committee members (5.3%) reported research funding for clinical studies focused on PDE-ALDH7A1.

2.3 | Systematic literature review

A systematic literature search of MEDLINE and Cochrane Library was performed for manuscripts published between January 2005 and December 2019. Key search terms included pyridoxine-dependent epilepsy, pyridoxine-dependent seizures, pyridoxine-responsive epilepsy, pyridoxine-responsive seizures, antiquitin deficiency, α-AASA dehydrogenase, and ALDH7A1. All data was collected and analyzed using the revtools package written for the statistical software R. The initial search identified 742 peer-reviewed publications. After a manual review by the guideline committee, five articles were added for a total of 747 abstracts. After duplicates were removed, a total of 336 abstracts were reviewed. Only those abstracts published in the English language and those that included clinical findings in patients with PDE due to a deficiency of α-AASA dehydrogenase were included. This was defined by the elevation of α-AASA/Δ¹-P6C in plasma, urine, or cerebral spinal fluid (CSF) or the presence of biallelic mutations in ALDH7A1. A total of 174 abstracts were accepted as relevant and their full-text articles were reviewed resulting in the final synthesis of 109 full-text articles (Figure S1). The literature review was initially performed by committee members (CRC, LAT, CDMvK) and shared with the guideline development group.

2.4 | Grading and strength of recommendations

The guideline committee members used the Grading of Recommendation Assessment, Development and
Evaluation (GRADE)\(^3\) approach to assessing evidence for each statement. The quality of evidence was graded as high, moderate, low, or very low as described in the GRADE consensus documents (Table 1). The quality assessment of the evidence was influenced by study design (ie, randomized trial compared to observational study), risk of bias, and size of effect reported in the literature. The GRADE system offers two categories of recommendations often referred to as "strong" and "weak." These categories are typically based on the quality of evidence or the impact of a treatment.\(^3\) To date, there have been no prospective randomized controlled trials to assess diagnostic approaches or management of PDE-ALDH7A1. This results in relatively low levels of evidence as most published studies are based on observational study designs and expert opinion. As a result, this guideline is highly dependent on expert opinion, which is not unique for clinical guidelines for inborn errors of metabolism.\(^3\) The strength of recommendation provided herein is based on whether the recommendation can apply to most patients in most circumstances and the high degree of agreement (Table 1). A statement received a strong recommendation when there was at least 90% agreement (completely agree or mostly agree) among the PDE experts.

### 2.5 Consensus procedure

The consensus procedure consisted of two online surveys and one in-person meeting (Figure S2). The surveys were created and distributed using Survey Monkey Inc. (San Mateo, California). An initial survey was developed by the guideline committee and included 29 statements focused on definition and epidemiology, clinical findings, diagnostic investigations, chronic treatment, chronic treatment monitoring, and emergency management. Each statement was evaluated using a 5-point Likert scale as follows: completely agree, mostly agree, partially agree, mostly disagree, completely disagree. The consensus was defined as at least 66% agreement (completely agree or mostly agree) or disagreement (mostly disagree or completely disagree). The initial survey was sent to 49 members of the PDE Consortium, was available for 6 weeks, and 25 individual responses were received. Consensus was reached for 27 of 29 statements (>85% agreement N = 14; 67%-84% agreement N = 13; <67% N = 2).

The results of the survey were discussed at the in-person meeting. A second survey was developed based upon the initial survey results and discussion of the nominal group at the in-person meeting. The Appraisal of Guidelines for Research and Evaluation (AGREE II) criteria was used as a guide.\(^3\) One additional statement was added regarding patient outcome collection and future guideline updates. The revised statements were sent to the 49 members of the PDE Consortium, was available for 10 weeks, and 29 responses were received. Consensus for the updated statements was reached for 29 of 30 statements (>85% agreement N = 22; 67%-84% agreement N = 7; <67% agreement N = 1) (Table S1). The proposed clinical guidelines were also reviewed by two patient advocacy groups based in Europe and North America, respectively.

### 3 RECOMMENDATIONS

#### 3.1 Definition and epidemiology

**Statement 1** PDE-ALDH7A1 is caused by bi-allelic mutations in the ALDH7A1 gene. Mutations in this gene are associated with decreased activity of α-aminoadipic semialdehyde dehydrogenase (α-AASA) and result in the accumulation of piperolic acid, Δ\(^1\)-piperidine-6-carboxylate (Δ\(^1\)-P6C), and α-AASA

<table>
<thead>
<tr>
<th>Level of evidence</th>
<th>Definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>High-quality evidence Randomized control studies, high confidence in effect estimates</td>
</tr>
<tr>
<td>B</td>
<td>Moderate-quality evidence Cohort studies, moderately confident in effect estimate</td>
</tr>
<tr>
<td>C</td>
<td>Low-quality evidence Observational studies, confidence in effect estimate is limited</td>
</tr>
<tr>
<td>D</td>
<td>Very-low quality evidence Expert opinions, limited confidence in the effect estimate</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Strength of recommendations</th>
<th>Definitions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Strong recommendation</td>
<td>Recommendation applies to most patients in most circumstances and with high expert agreement(^a) (≥90% of respondents)</td>
</tr>
<tr>
<td>2 Conditional recommendation</td>
<td>Alternative approaches are reasonable depending on circumstances and with limited expert agreement (&lt;90% of respondents)</td>
</tr>
</tbody>
</table>

\(^a\)Agreement was defined by the percentage of respondents who either answered "completely agree" or "mostly agree".
The genetic etiology of PDE-ALDH7A1 was initially identified in patients with the clinical phenotype of pyridoxine responsive and dependent epilepsy. There have been multiple larger case series that have consistent data suggesting that the clinical phenotype of PDE-ALDH7A1 is associated with mutations in \textit{ALDH7A1}.\textsuperscript{6,15,20,21,40} Increased $\alpha$-AASA and $\Delta^1$-P6C were reported in patients with PDE compared to a control group including those with epilepsy and normal controls.\textsuperscript{16,18} There are no patients described in the literature with biallelic mutations in \textit{ALDH7A1} and normal AASA/P6C. Increased pipecolic acid has been described in patients with PDE-ALDH7A1, however, normal pipecolic acid levels have also been found when patients were tested while treated with pyridoxine.\textsuperscript{12,41}

\textbf{Statement 2} PDE-ALDH7A1 is [a] rare disease with an estimated incidence of 1:65 000 to 1:250 000 live births. PDE-ALDH7A1 is pan-ethnic and >98% of all patients have bi-allelic mutations in \textit{ALDH7A1}.

3.2 | \textbf{Clinical presentation}

\textbf{Statement 3} PDE-ALDH7A1 is characterized by an epileptic encephalopathy with varying degree of intellectual disability or developmental delay.

3.3 | \textbf{Diagnostic investigations}

\textbf{Statement 5} All individuals with an unexplained seizure disorder should be tested for PDE-ALDH7A1.
• Level of evidence: C
• Strength of recommendation: 2
• Expert opinion: completely agree (60.7%), mostly agree (21.4%), partially agree (14.3%), mostly disagree (3.6%), completely disagree (0%)

The initial guideline recommendations stated that PDE-ALDH7A1 should be considered in some clinical scenarios including seizures of unknown etiology, infants and children with seizures which are partially responsive to antiseizure medications, and children under 1 year of age without an apparent causal brain malformation.25 Since those initial guidelines were published, some patients have presented after 1 year of age and into late adolescence. There is not a well-defined electrographic signature that is pathognomonic for either neonatal-onset or late-onset PDE-ALDH7A1,3 which emphasizes the importance of testing for this disease in the absence of an established etiology. Prospective genetic evaluations of patients with epilepsy have identified patients with PDE-ALDH7A1 that were otherwise not diagnosed.50 Recent recommendations have included testing all children with seizures of unknown etiology.51

Statement 6 Diagnostic biomarkers include α-AASA and Δ1-P6C, which can be measured in urine, blood, or cerebral spinal fluid. Pipecolic acid is elevated in urine, plasma, and cerebral spinal fluid in most patients with PDE-ALDH7A1. The biomarkers α-AASA/Δ1-P6C can be used alone or in combination with other biomarkers to increase sensitivity and specificity.

• Level of evidence: B
• Strength of recommendation: 1
• Expert opinion: completely agree (65.5%), mostly agree (34.5%), partially agree (0%), mostly disagree (0%), completely disagree (0%)

Statement 7 Genetic testing of ALDH7A1 should be performed as α-AASA/Δ1-P6C elevations have been reported in disorders of sulfite oxidase

• Level of evidence: D
• Strength of recommendation: 1
• Expert opinion: completely agree (69%), mostly agree (27.6%), partially agree (0%), mostly disagree (0%), completely disagree (3.4%)

Statement 8 Biallelic pathogenic variants in the ALDH7A1 gene is consistent with the diagnosis of PDE-ALDH7A1. Genetic testing is the only reliable method for carrier screening of family members and prenatal diagnosis. Biochemical testing should be performed when a single pathogenic variant or a variant of uncertain significance is identified.

• Level of evidence: B
• Strength of recommendation: 1
• Expert opinion: completely agree (82.8%), mostly agree (13.8%), partially agree (0%), mostly disagree (3.4%), completely disagree (0%)

Historically, the diagnosis of PDE-ALDH7A1 was based upon the positive clinical response to pyridoxine. Unfortunately, patients may not have an immediate clinical or EEG response to a trial of pyridoxine and a positive clinical response is not unique to PDE-ALDH7A1.3,10 All affected patients with PDE-ALDH7A1 have been reported to have increased plasma or urine α-AASA/Δ1-P6C emphasizing the sensitivity of these biomarkers.16,18 Patients with molybdenum cofactor deficiency and isolated sulfite oxidase deficiency have been reported with mild elevations of α-AASA/Δ1-P6C due to secondary inhibition of α-AASA dehydrogenase.52,53 The diagnosis of PDE-ALDH7A1, molybdenum cofactor deficiency, or isolated sulfite oxidase deficiency can be confirmed by further biochemical testing or molecular genetic testing. Timely confirmation of molybdenum cofactor deficiency is paramount as disease-specific treatment is available.54

Pipecolic acid was the first biomarker identified in patients with PDE-ALDH7A1, although patients who are tested after pyridoxine treatment may have normal levels of pipecolic acid.12,41 Other biomarkers have been reported including peak X (an unidentified compound)55,56 and 6-oxo-pipecolate57,58 although the role of these biomarkers in diagnosis or treatment monitoring has yet to be established. Many clinicians have adopted the use of gene panels or genomic sequencing when patients are suspected to have a genetic disorder. In these cases, biochemical testing can confirm the diagnosis of PDE-ALDH7A1 when genetic testing is uninformative.

3.4 | General principles of treatment

Statement 9 All patients with PDE-ALDH7A1 should be treated with pyridoxine supplementation.

• Level of evidence: B
• Strength of recommendation: 1
• Expert opinion: completely agree (93.1%), mostly agree (6.9%), partially agree (0%), mostly disagree (0%), completely disagree (0%)
Pharmacologic doses of pyridoxine for pyridoxine-dependent seizures has been the mainstay of treatment since the identification of these seizures by Hunt et al. 1954, hence the name. Descriptive studies have reported patients with PDE-ALDH7A1 who died before pyridoxine was provided. Furthermore, the withdrawal of pyridoxine has been associated with recurrence of seizures, underscoring the necessity of pyridoxine in the treatment of PDE-ALDH7A1.

**Statement 10** Lysine reduction therapies have been associated with improved long-term neurologic outcomes. Therapies include pyridoxine supplementation in combination with a lysine-restricted diet or arginine supplementation and a combination of all three (ie, triple therapy)

- Level of evidence: C
- Strength of recommendation: 2
- Expert opinion: completely agree (65.5%), mostly agree (20.7%), partially agree (10.3%), mostly disagree (3.4%), completely disagree (0%)

The association between lysine reduction therapies and neurologic outcomes has been reported in a total of 10 observational studies describing 27 individual patients with PDE-ALDH7A1. These studies have reported improvement in seizure control and development in many but not all subjects. Unfortunately, several outcome measures were used in these studies ranging from subjective parental reports to formal neurocognitive testing, which limits the use of a meta-analysis. Other factors have been postulated to confound the impact of lysine reduction therapies including the timing of diagnosis and treatment.

**3.5 Treatment of newborns and infants**

**Statement 11** All newborns with PDE-ALDH7A1 should be treated with 100 mg/day of pyridoxine supplementation. Infants should be treated with 30 mg/kg/day of pyridoxine supplementation with a maximum dose of 300 mg/day.

- Level of evidence: D
- Strength of recommendation: 2
- Expert opinion: completely agree (50%), mostly agree (38.5%), partially agree (11.5%), mostly disagree (0%), completely disagree (0%)

Although the use of pharmacologic doses of pyridoxine has been well supported, the dose of pyridoxine for newborns, infants, children, and adults is based on observational data and expert opinions. In the initial guidelines, a diagnostic trial of pyridoxine was recommended at 100 mg given intravenously and repeated up to four times (maximal dose 500 mg). It is important to note that intravenous pyridoxine is not without risk as apnea and comatose state have been reported after the initial intravenous dose of pyridoxine. Although lower doses of pyridoxine have been reported, the recommended dose of pyridoxine for long term management was 15-30 mg/kg/day in infants and up to 200 mg/day in neonates.

**Statement 12** All newborns and infants with PDE-ALDH7A1 should be treated with lysine reduction therapies

- Level of evidence: D
- Strength of recommendation: 1
- Expert opinion: completely agree (65.5%), mostly agree (27.6%), partially agree (6.9%), mostly disagree (0%), completely disagree (0%)

As noted above, the benefit of lysine reduction therapies has been limited to case reports and case series. Of note, two studies focused on the benefit of lysine reduction therapies in patients under the age of 1 year. Even in patients who were treated in the first months of life, pretreatment sequelae were noted on brain MRI and in a larger retrospective review, add-on treatment after 7 months of age was associated with poor neurologic outcome.

**Statement 13** In newborns and infants, a lysine-restricted diet should include a lysine-free amino acid formula in order to maintain adequate total protein and micronutrient intake and low-normal plasma lysine level.

- Level of evidence: D
- Strength of recommendation: 1
- Expert opinion: completely agree (69%), mostly agree (27.6%), partially agree (3.4%), mostly disagree (0%), completely disagree (0%)

The first revision to the guidelines was focused on the use of a lysine-restricted diet, and encouraged breastfeeding as the average protein content of breast milk is considerably lower than that of formula milk. The use of a lysine-free formula with amino acid supplementation was also recommended to ensure both the limitation of lysine and appropriate intake of nutritional supplementation. It is important to note that the majority of lysine-free formulas are designed for glutaric
aciduria type I, which is a disorder of both lysine and tryptophan metabolism and therefore is also low in tryptophan.\textsuperscript{70}

**Statement 14** In newborns and infants, arginine supplementation should be started at a dose of 200 mg/kg/day whether arginine is provided alone or in combination with a lysine-restricted diet.

- **Level of evidence:** D
- **Strength of recommendation:** 2
- **Expert opinion:** completely agree (50%), mostly agree (25%), partially agree (14.3%), mostly disagree (3.6%), completely disagree (7.1%)

Pharmacologic doses of arginine have been used to compete with lysine for intestinal absorption as well as the transport over the blood-brain barrier and entry into the mitochondria. Arginine has been used with both pyridoxine alone\textsuperscript{29} and in combination with a lysine-restricted diet and pyridoxine.\textsuperscript{30-32} The dose of arginine for newborn, children and adults are based on observational data and expert opinions. Previous recommendations for arginine dosing recommended 150 mg/kg/day if administered in addition to a lysine-restricted diet and 400 mg/kg/day if administered with pyridoxine alone.\textsuperscript{71} A recent study using stable isotopes to measure lysine oxidation in healthy adult volunteers suggested a higher dose of arginine may be required to impact lysine transport.\textsuperscript{72} Pharmacologic doses of arginine are also used in other disorders. In randomized controlled trials evaluating the use of arginine in preterm infants at risk for necrotizing enterocolitis, the mean dose of arginine was 261 mg/kg/day with no adverse events reported.\textsuperscript{73-75} Arginine is recommended for the long-term treatment of most urea cycle disorders other than arginase deficiency. The dose of arginine in neonates and infants with urea cycle disorders ranges from 100 to 300 mg/kg/day and a dose of 2.5-6 g/m\textsuperscript{2}/day is recommended in patients who weigh more than 20 kg.\textsuperscript{76}

### 3.6 Treatment of children and adolescents

**Statement 15** Children and adolescents with PDE-ALDH7A1 should be treated with an average of 20 mg/kg/day (range 5-30 mg/kg/day) of pyridoxine with a maximum dose of 500 mg/day.

- **Level of evidence:** D
- **Strength of recommendation:** 1
- **Expert opinion:** completely agree (59.3%), mostly agree (33.3%), partially agree (3.7%), mostly disagree (3.7%), completely disagree (0%)

**Statement 16** All children and adolescents with PDE-ALDH7A1 should be offered treatment with lysine reduction therapies. Children and adolescents with cognitive delay, behavioral difficulties, or poor seizure control should be treated with lysine reduction therapies.

- **Level of evidence:** D
- **Strength of recommendation:** 2
- **Expert opinion:** completely agree (58.6%), mostly agree (27.6%), partially agree (10.3%), mostly disagree (3.4%), completely disagree (0%)

**Statement 17** In children and adolescents, a lysine-restricted diet may include a lysine-free amino acid formula. If a lysine-free formula is not well tolerated, lysine reduction may be achieved by reducing total natural protein to the low end of age-appropriate needs.

- **Level of evidence:** D
- **Strength of recommendation:** 2
- **Expert opinion:** completely agree (44.8%), mostly agree (37.9%), partially agree (10.3%), mostly disagree (6.9%), completely disagree (0%)

In the previous update to the PDE guidelines, a protein-restricted diet was recommended when a lysine-free formula was unavailable or if a patient did not tolerate the formula.\textsuperscript{35} Patients treated with protein-restricted diets, as well as pharmacologic doses of arginine and pyridoxine, had similar reductions in biochemical parameters and improved clinical outcomes. It is important to balance natural protein levels to both meet age-appropriate protein needs and reduce lysine oxidation. This emphasizes the importance of anmetabolic dietitian as part of the clinical team.

Statement 18 focused on the dose of arginine in children and adolescents with a suggested dose of 200 mg/kg/day and a maximum dose of 600 mg/kg/day. Despite being included in both surveys and discussion at the in-person meeting, a consensus was not reached. Therefore, the statement is not provided in this manuscript although the proposed statement, expert opinion, and comments from guidelines members are available in Table S1.

### 3.7 Treatment of adults

**Statement 19** All adults with PDE-ALDH7A1 should be treated with 200-500 mg/day of pyridoxine.

- **Level of evidence:** D
- **Strength of recommendation:** 2
- **Expert opinion:** completely agree (66.7%), mostly agree (18.5%), partially agree (11.1%), mostly disagree (3.7%), completely disagree (0%)
As noted above, the dose of pyridoxine for adults is based on observational data and expert opinions. In the initial guidelines, the maximum recommended dose of pyridoxine was 500 mg/day in adults.\textsuperscript{25}

**Statement 20** All adults with PDE-ALDH7A1 should be offered treatment with lysine reduction therapy. Adults with cognitive delay, behavioral difficulties, or poor seizure control should be treated with lysine reduction therapies

- Level of evidence: D
- Strength of recommendation: 2
- Expert opinion: completely agree (55.2%), mostly agree (13.8%), partially agree (27.6%), mostly disagree (3.4%), completely disagree (0%)

**Statement 21** In adults, lysine reduction may be achieved by reducing total natural protein to the low end of age-appropriate needs

- Level of evidence: D
- Strength of recommendation: 1
- Expert opinion: completely agree (51.9%), mostly agree (40.7%), partially agree (7.4%), mostly disagree (0%), completely disagree (0%)

**Statement 22** In adults, arginine supplementation should be started at 4 g/m\textsuperscript{2}/day with a maximum dose of 5.5 g/m\textsuperscript{2}/day

- Level of evidence: D
- Strength of recommendation: 2
- Expert opinion: completely agree (29.2%), mostly agree (45.8%), partially agree (12.5%), mostly disagree (12.5%), completely disagree (0%)

As noted above, the benefit of lysine reduction therapies has been limited to case reports and case series and the impact of treatment in adults is still unclear. Thus, these recommendations are dependent on expert opinion. As noted above, arginine is recommended for long-term treatment of most urea cycle disorders, and the dose of 2.5-6 g/m\textsuperscript{2}/day is recommended in patients who weigh more than 20 kg.\textsuperscript{76} And in adults with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) a dose of 150-500 mg/kg/day is recommended.\textsuperscript{77,78}

### 3.8 Treatment monitoring

**Statement 23** All patients treated with pyridoxine supplementation should have clinical screening for peripheral neuropathy including assessment of deep tendon reflexes. Patients who are treated with > 500 mg/day of pyridoxine may be at higher risk of peripheral neuropathy and further evaluation with electrodiagnostic testing may be warranted

- Level of evidence: C
- Strength of recommendation: 2
- Expert opinion: completely agree (82.8%), mostly agree (6.9%), partially agree (6.9%), mostly disagree (0%), completely disagree (3.4%)

In the initial guidelines, patients treated with >500 mg/day of pyridoxine were recommended to have screening for peripheral neuropathy.\textsuperscript{25} Case reports of patients with PDE who had documented neuropathy were treated with relatively high doses of pyridoxine, although one of these patients did not have genetic or biochemical confirmation of PDE-ALDH7A1.\textsuperscript{45,79} Adult patients with homocystinuria have also been reported with a sensory neuropathy at doses > 1000 mg/day.\textsuperscript{80} In a systematic review of peripheral neuropathy associated with pyridoxine, authors suggested that even doses as low as 50 mg/day of pyridoxine used for greater than 6 months may increase the risk of neuropathy.\textsuperscript{81} A clinician skilled in the performance of electrodiagnostic testing (specifically, measurements of sensory and motor nerve conduction velocities) in young patients may not practice in all centers caring for patients with PDE-ALDH7A1. If this resource is available, screening electrodiagnostic testing every 1-2 years should be considered in cases of a higher dose of pyridoxine or based upon clinical suspicion of neuropathy. In patients with symptomatic peripheral neuropathy or in whom there is neurophysiological evidence of progressive neuropathy, a reduction in pyridoxine dose may need to be considered and weighed against a possible deterioration of seizure control.

**Statement 24** All patients treated with a lysine-restricted diet should have plasma amino acids measured at least every 3 (<3 years of age) to 6 months (>3 years of age)

- Level of evidence: D
- Strength of recommendation: 1
- Expert opinion: completely agree (72.4%), mostly agree (20.7%), partially agree (6.9%), mostly disagree (0%), completely disagree (0%)

Amino acid concentrations are used to individually tailor the lysine-restricted diet, and the previous guidelines recommended plasma lysine should remain in the lower quartile of the reference range.\textsuperscript{35} Lysine is an essential
amino acid and over restriction of lysine has the potential risk of malnutrition. In patients with glutaric aciduria type I, an appropriately administered low lysine diet prevented malnutrition and was able to promote normal weight gain, although patients should be closely monitored especially during periods of rapid growth. As a result, dietary treatment should be supervised by a metabolic dietitian.

**Statement 25** All patients on lysine-reduction therapies should have plasma and urine biomarkers \( \Delta^1-P6C \) and/or \( \alpha \)-AASA measured every 6-12 months to assess treatment efficacy

- Level of evidence: D
- Strength of recommendation: 2
- Expert opinion: completely agree (41.4%), mostly agree (41.4%), partially agree (17.2%), mostly disagree (0%), completely disagree (0%)

**Statement 26** If a lumbar puncture is performed, CSF \( \Delta^1-P6C \), \( \alpha \)-AASA, pyridoxal 5'-phosphate, pipecolic acid, neurotransmitters, and amino acids should be measured to assess treatment efficacy

- Level of evidence: D
- Strength of recommendation: 2
- Expert opinion: completely agree (58.6%), mostly agree (20.7%), partially agree (13.8%), mostly disagree (6.9%), completely disagree (0%)

A small number of observational studies have reported the impact of treatment on CSF metabolites. Compared to pre-treatment levels, patients treated with lysine reduction therapy have shown an increase in CSF arginine and a decrease in CSF lysine and \( \alpha \)-AASA. Further studies are required to determine if there is an association between these metabolites and clinical outcomes. Minor elevations of other CSF amino acids and decrease in 5-methyltetrahydrofolate have been noted in patients with PDE-ALDH7A1, although these findings may be due to a deficiency of pyridoxal 5'-phosphate. Historically abnormal gamma-aminobutyric acid (GABA) metabolism was suggested to be the underlying cause of PDE, although CSF glutamate and GABA are typically in the normal range. As noted previously, most lysine-free formulas are low in tryptophan. One PDE patient treated with a lysine-free and low tryptophan formula was noted to have a mild serotonin deficiency (low 5-hydroxyindoleacetic acid).

**Statement 27** All patients with PDE-ALDH7A1 should have developmental evaluations to assess treatment efficacy. Developmental assessments should be age-appropriate, started at the time of diagnosis, and repeated at the start of school or when there is clinical concern of developmental delay

- Level of evidence: D
- Strength of recommendation: 1
- Expert opinion: completely agree (82.8%), mostly agree (13.8%), partially agree (3.4%), mostly disagree (0%), completely disagree (0%)

### 3.9 | Emergency treatment

**Statement 28** In times of seizure relapse during febrile illness, the dose of pyridoxine may be doubled up to a maximum of 60 mg/kg/day (in children) or 500 mg/day (adolescents and adults) for up to 3 days

- Level of evidence: D
- Strength of recommendation: 1
- Expert opinion: completely agree (62.1%), mostly agree (31%), partially agree (3.4%), mostly disagree (3.4%), completely disagree (0%)

**Statement 29** In times of illness, ensure adequate caloric intake to prevent catabolism of endogenous protein and reduce protein intake

- Level of evidence: D
- Strength of recommendation: 1
- Expert opinion: completely agree (67.9%), mostly agree (25%), partially agree (3.6%), mostly disagree (3.6%), completely disagree (0%)

In the previous versions of the guidelines, higher dosages of pyridoxine during the first 3 days of febrile illness and maintenance of caloric intake to prevent catabolism were recommended. These recommendations are based on expert opinion as there is no data on efficacy or safety of the increased dose of pyridoxine in this setting. Further studies are needed to elucidate whether and which emergency treatments are warranted during times of illness or other catabolic stress.

### 3.10 | Guideline update

**Statement 30** In order to assess the efficacy of these recommendations, patient outcomes should be systematically collected in the PDE patient registry. New evidence on treatment efficacy or impact of treatment on patients will be reviewed by the
International PDE Consortium for immediate response or more detailed consideration of an update to the existing guideline.

- Strength of recommendation: 1
- Expert opinion: completely agree (96.4%), mostly agree (3.6%), partially agree (0%), mostly disagree (0%), completely disagree (0%)

Using the AGREE II instrument as a guide, we propose a procedure for updating the guideline for diagnosis and management of patients with PDE-ALDH7A1. Specifically, we recommend using the existing PDE patient registry to collect patient outcomes which will be evaluated by the International PDE Consortium. Patient registries can provide a helpful structure for the collection of uniform data to evaluate specified outcomes for a specific population. Patient registries can be used for several purposes including elucidation of the natural history of the disease course or treatment outcomes. Patient registries can be used for clinical trial designs in many ways and if well designed and well-performed, studies from patient registries can provide a real-world view of these outcomes. Due to low prevalence and often scarcity of data, (international) collaboration and optimal use of limited resources by data sharing is recommended.

4 | CONCLUSIONS

These guidelines address the diagnosis and management of PDE-ALDH7A1 and are based on the best available evidence. With these guidelines, we aim to facilitate clinical decision making and improve the care for patients with PDE-ALDH7A1 in a standardized manner.

The ability to diagnose PDE-ALDH7A1 has dramatically improved with the identification of multiple biomarkers and the increased availability of genetic testing. One limitation may be that not every clinician is aware of the significant phenotypic heterogeneity in this disease. This may explain why the diagnosis of PDE-ALDH7A1 is delayed even when patients present with classical symptoms such as neonatal epileptic encephalopathy. The clinical semiology of this rare disease may be improved through the collaboration of the International PDE Consortium and the PDE patient registry. Although there is limited evidence, the present guidelines support that lysine-reduction therapies should be started early in life for optimal neurologic outcomes. Next-generation sequencing epilepsy panels and genomic sequencing aid in the diagnosis of new patients all around the world, especially in countries with difficult access to biochemical analysis. In the future, newborn screening may provide an opportunity to identify all patients with PDE-ALDH7A1 regardless of presentation and ensure treatment is initiated before further damage occurs.

Although the phenotype of PDE was described over 65 years ago, the most frequent underlying genetic defect, namely a deficiency of α-AASA dehydrogenase, was described less than 15 years ago. Evidence for the benefit of lysine reduction therapies has been limited given that only observational studies have been performed. Questions remain about whether lysine reduction therapies are beneficial in all patients. Even so, there is optimism that the combination of pyridoxine and lysine reduction therapies can improve the poor cognitive outcome pervasive in this disease. We did not reach consensus on the statement regarding the dosage of arginine for both children and adolescents.

The evidence for many of the recommendations are limited and, as a result, these guidelines are highly dependent on expert opinion. It is imperative to continually evaluate the evidence that supports these recommendations and establish meaningful clinical outcomes to evaluate current and future therapies for PDE-ALDH7A1. Since prospective randomized controlled trials in rare diseases are difficult, the International PDE registry (www.pdeonline.org) provides a great opportunity to systematically collect the impact of these recommendations for the diagnosis and management of these patients.

ACKNOWLEDGEMENTS

P. B. M. and P. T. C. are supported by the National Institute for Health Research Biomedical Research Centre at GOSH for Children NHS Foundation Trust and University College London. P. S. was supported with the framework of the DINOGMI, Department of Excellence of MIUR 2018-2022 (Legge 232 del 2016).

We are grateful to Ms. Petra Hollak (patient advocacy organization VKS: Dutch Patient Organization for Metabolic Diseases) as well as Ms. Jennifer Sibit and Ms. Leah Trotter (parents of children with PDE-ALDH7A1) for their insightful edits to the manuscript.

CONFLICT OF INTEREST

C. R. C. and J. V. H. have a patent pending on the use of 6-oxo-pipecolate in the diagnosis of PDE. P. S. has received speaker fees and participated at advisory boards for Biomarin, Zogenyx, GW Pharmaceuticals, and has received research funding by ENECTA BV, GW Pharmaceuticals, Kolfarma srl., Eisai. S. Z. has received research funding through the Dravet Syndrome UK, Epilepsy Research UK, Tenovus Foundation, Ring Chromosome 20 Research & Support, NHS Scotland Digital Health & Care, UCB Pharma, Zogenix Inc, GW Pharma; has received honorarium and payment for lectures from Biocodex, Zogenix, GW Pharma; and has received consultancy fees...
from Encoded Genomics. L. A. T. and C. D. M. v. K. report research funding from Vitaflo. All other authors have no conflicts to declare. The ICMJE form for disclosure of potential conflicts of interest is provided for every author.

AUTHOR CONTRIBUTIONS

Curtis R. Coughlin II, Laura A. Tseng, Clara D.M. van Karnebeek lead the systematic review, development of the initial statements, reviewed comments, and drafted the manuscript. Jose E. Abdenur, Catherine Ashmore, François Boemer, Levinus A. Bok, Monica Boyer, Daniela Buhas, Peter T. Clayton, Anihb Das, Athanasios Evangeliou, François Feillet, Emma J. Footitt, Sidney M. Gospe Jr, Hans Hartmann, Majdi Kara, Erle Kristensen, Joy Lee, Rina Lilje, Nicola Longo, Philippa Mills, Maria T. Papadopoulou, Phillip L. Pearl, Flavia Piazzon, Barbara Plecko, Arushi G. Saini, Saikat Santra, Damayanti R. Sjarif, Sylvia Stockler-Curtis R. Coughlin II agreed to be accountable for the final version of the manuscript and contributed to the final manuscript. All authors critically reviewed and contributed to the final manuscript and agreed to be accountable for the final version of the manuscript.

ETHICS STATEMENT

This manuscript is not human subject research. No ethics approval or informed consent was required.

ORCID

Curtis R. Coughlin II https://orcid.org/0000-0002-3545-7903

REFERENCES


